Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central
Privacy Policy
|  |
Fc receptors as potential targets for the treatment of allergy, autoimmune disease and cancer.
Takai T, Nakamura A, Akiyama K.
Department of Experimental Immunology and CREST Program of Japan Science and Technology Corporation, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan. tostakai@idac.tohoku.ac.jp
The activation threshold of various cells in the immune system is tuned by immune inhibitory receptors. The inhibitory Fc receptor, FcgammaRIIB, is one of the critical elements for keeping immune cells silent. Murine models for allergic responses and autoimmune diseases illustrate the indispensable roles of FcgammaRIIB in the suppression of these immune disorders. On the contrary, activating-type Fc receptors are crucial for the onset and exacerbation of such diseases. In addition, recent reports have revealed the pivotal roles of Fc receptors in enhancing antigen presentation by dendritic cells, which leads to efficient major histocompatibility complex class I- and class II-restricted T cell activation. In this context, anti-cancer immunopotentiation could be augmented by targeting the tumor antigens to Fc receptors on dendritic cells. This review summarizes recent advances in Fc receptor biomedicine in light of exploiting them as potential therapeutic targets for allergy, autoimmune disease and cancer.
PMID: 12871025 [PubMed - in process]
|